Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines

• Published in: Vaccine Vol. 16; no. 13; pp. 1270 - 1275
• Main Authors: Salmaso, Stefania, Mastrantonio, Paola, Wassilak, Steven G.F, Giuliano, Marina, Anemona, Alessandra, Giammanco, Anna, Tozzi, Alberto E, Ciofi degli Atti, Marta L, Greco, Donato
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01-08-1998; Elsevier
• Subjects: acellular vaccine; Bacteriology; Biological and medical sciences; efficacy; Epidemiology. Vaccinations; Fundamental and applied biological sciences. Psychology; General aspects; Infectious diseases; Medical sciences; Microbiology; Pathogenicity, virulence, toxins, bacteriocins, pyrogens, host-bacteria relations, miscellaneous strains; pertussis; Southern Europe; Italy; Europe; acellular vaccine; pertussis; efficacy; Human; Performance evaluation; Immunoprotection; Response duration; Bordetella pertussis; Whooping cough; Infection; Persistence; Follow up study; Bacteriosis; Acellular vaccine; Bacteria; Child; Comparative study
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/S0264-410X(98)00040-1

A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, one manufactured by SmithKline and Beecham (SB) and one by Chiron Biocine (CB), found each vaccine to be 84% efficacious through the average age of 24 months. The cohort of children envolled in the trial was followed with unmodified case ascertainment procedures for nine additional calendar months, during which partial unblinding occurred, for the unvaccinated randomized group. For the DTaP groups, the specific vaccine assignment remained double-blinded throughout the entire additional observation period. Pertussis was defined as paroxysmal cough lasting at least 21 days and confirmed by culture or serology. In the additional 9 months the observed absolute efficacy was 78% (95% CI, 62–87%) for SB DTaP vaccine and 89% (95% CI, 79–94%) for CB DTaP. The relative risk of developing pertussis in SB DTaP recipients compared to CB DTaP vaccinees was 1.99 (95% CI, 1.13–3.51). By combining observations from the initial and additional follow-up periods, the overall observed vaccine efficacy through an average age of 33 months of SB DTaP was 80% and of CB DTaP, 85%